Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells (MSV_LE)
Phase II, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate Safety and Efficacy of Mesenchymal Stem Cells (MSV-allo) in the Treatment of Lupus Nephritis
Sponsor: Citospin
Listed as NCT03673748, this PHASE2 trial focuses on Lupus Erythematosus and Lupus Nephritis and remains actively recruiting participants. Sponsored by Citospin, it has been updated 15 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
15 versions recorded-
Aug 2025 — Present [monthly]
Recruiting PHASE2
-
Nov 2024 — Aug 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 10 earlier versions
-
May 2023 — May 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2023 — May 2023 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2022 — Jan 2023 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2021 — Jul 2022 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2019 — Apr 2020 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2018 — Dec 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Citospin
- Hospital Clínico Universitario de Valladolid
- Hospital del Rio Hortega
- Red de Terapia Celular
- University of Valladolid
For direct contact, visit the study record on ClinicalTrials.gov .